Charcot neuro-osteoarthropathy

Diabetes Metab Res Rev. 2008 May-Jun:24 Suppl 1:S62-5. doi: 10.1002/dmrr.837.

Abstract

The classical neurotraumatic and neurotrophic theories for the pathogenesis of the acute Charcot neuro-osteoarthropathy (CN) in diabetes, do not address certain key features of the disease. These features include the facts that the condition usually affects just one side, that it is self-limiting, and that it is also very uncommon. Similarly, it is not known to what extent the condition may depend, as suggested by Jean-Martin Charcot, on pre-morbid osteopenia. Recent advances in understanding the mechanisms underlying the pathogenesis of osteopenia and osteoporosis and the central role of the RANKL/OPG signalling system have, however, suggested the possible involvement of other factors in the evolution of the disease. Specifically, it has been suggested that acute CN may be triggered in a susceptible individual by any event that leads to localized inflammation in the affected foot. This local inflammation leads to a vicious cycle in which there is increasing inflammation, increasing expression of RANKL, and increasing bone breakdown. The likely central role for the RANKL/OPG pathway suggests new possibilities for future treatments.

Publication types

  • Review

MeSH terms

  • Arthropathy, Neurogenic / physiopathology*
  • Arthropathy, Neurogenic / therapy
  • Bone Diseases, Metabolic / physiopathology*
  • Disease Progression
  • Humans
  • Inflammation / physiopathology